STOCK TITAN

374Water Inc. Form 4 Filings

SCWO NASDAQ

Every Form 4 that 374Water Inc. (SCWO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow SCWO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCWO filings page.

Rhea-AI Summary

374Water Inc. reported that Chief Financial Officer Charles Maurice Weiser received new equity awards as part of his compensation. He was granted 125,000 restricted stock units and stock options for 150,000 shares of common stock at an exercise price of $2.16 per share on July 1, 2026. Both the RSUs and options vest 25% on the grant date and the remaining 75% in 12 equal quarterly installments starting October 1, 2026, aligning his incentives with the company’s long-term performance.

Rhea-AI Summary

374Water Inc. Chief Operating Officer Brad Ian Meyers reported selling common shares in the open market. The Form 4 shows two non-derivative transactions: an open-market sale of 9,000 shares of common stock at $2.46 per share and a separate open-market sale of 9,831 shares at $2.33 per share, for a total of 18,831 shares sold. The filing also lists his remaining direct common stock holdings after these transactions.

Rhea-AI Summary

374Water Inc. major shareholder Yaacov Nagar reported a large share gift. On this Form 4, Nagar made a bona fide gift transfer of 1,440,000 shares of 374Water common stock at an indicated value of $2.48 per share.

After the gift, Nagar directly holds 1,771,263 shares of common stock. Because this was a gift rather than a market sale, it reflects a change in how the shares are held, not an open‑market transaction.

Rhea-AI Summary

374Water Inc.'s chief financial officer reports a personal stock purchase. On December 16, 2025, the CFO acquired 20,000 shares of 374Water Inc. common stock at a price of $0.22 per share. After this transaction, the officer directly holds 668,642 shares of the company’s common stock. This filing reflects an insider increasing their direct ownership stake in the company.

Rhea-AI Summary

374Water Inc. reported an insider stock purchase by its interim CEO and director. On 12/16/2025, a reporting person serving as both a director and Interim CEO acquired 450,000 shares of 374Water Inc. common stock in an open market transaction coded "P" for purchase.

The shares were bought at a price of $0.2311 per share. After this transaction, the reporting person beneficially owned a total of 1,055,723 common shares, held directly. The filing is presented as a single‑person Form 4, highlighting this one notable equity purchase and confirming direct ownership status following the trade.

Rhea-AI Summary

374Water (SCWO): A 10% owner reported open‑market sales of common stock. On 10/22/2025, 61,000 shares were sold at a weighted‑average price of $0.421. On 10/23/2025, 473,211 shares were sold at a weighted‑average price of $0.434, executed in multiple trades within disclosed ranges. Following these transactions, beneficial ownership stood at 32,112,632 shares, held directly.

The prices reflect weighted averages; detailed trade prices within the ranges are available upon request as noted.

Rhea-AI Summary

374Water Inc. (SCWO) reported an insider equity award. The company’s Chief Technology Officer received a grant of 500,000 stock options at an exercise price of $0.60 per share on October 9, 2025, as disclosed on a Form 4.

The options were awarded as a special retention incentive tied to continued service. Vesting occurs over two years: 50% on the first anniversary of the grant date and the remaining 50% on the second anniversary, subject to continued service. In the event of an involuntary termination without cause, all remaining unvested options will vest immediately. Each option is exercisable for one share of common stock upon vesting and expires ten years from the grant date unless earlier terminated under the grant agreement. Following the award, 500,000 derivative securities were beneficially owned directly.

Rhea-AI Summary

374Water (SCWO) disclosed insider share sales by a reporting person identified as a 10% owner. On 10/20/2025, the holder sold 13,330 shares of common stock at a weighted‑average price of $0.4208; on 10/21/2025, 284,394 shares at $0.4204; and on 10/22/2025, 32,791 shares at $0.4209.

After these transactions, the reporting person beneficially owned 32,646,843 shares, held directly. Each day’s sale was executed in multiple trades within stated price ranges: $0.4202–$0.4211, $0.420–$0.4208, and $0.4207–$0.4210, respectively.

Rhea-AI Summary

374Water (SCWO) filed a Form 4 reporting sales by 10% owner Yaacov Nagar. On 10/16/2025, he sold 85,419 shares at a weighted-average price of $0.5126, leaving 33,109,038 shares beneficially owned directly. On 10/17/2025, he sold 131,680 shares at a weighted-average price of $0.423, with direct ownership at 32,977,358 shares after the reported transactions. The trades were executed in multiple lots within price ranges of $0.5108–$0.5140 and $0.4200–$0.4383.

Rhea-AI Summary

374Water (SCWO) insider transaction: A reporting person filed a Form 4 disclosing open‑market sales of common stock on two dates. On 10/14/2025, they sold 700,000 shares at a weighted‑average price of $0.5163. On 10/15/2025, they sold 363,868 shares at a weighted‑average price of $0.5179.

Following these transactions, the reporting person beneficially owned 33,194,457 shares. The prices reflect weighted averages from multiple trades executed within disclosed intraday ranges.

Rhea-AI Summary

374Water (SCWO) reported a Form 4 for its Chief Financial Officer, showing a grant of 500,000 stock options on 10/09/2025 at an exercise price of $0.6 per share. The filing lists 808,642 derivative securities beneficially owned after the transaction.

According to the award terms, 50% of the options vest on the first anniversary of the grant date and the remaining 50% vest on the second anniversary, subject to continued service. Unvested options fully vest upon an involuntary termination without cause. The options expire ten years from the grant date, unless terminated earlier under the grant agreement.

Rhea-AI Summary

374Water Inc. (SCWO) reported a Form 4 showing its Chief Operating Officer received a grant of 500,000 stock options on 10/09/2025 at an exercise price of $0.60 per share.

According to the award terms, 50% of the options vest on the first anniversary of the grant date and the remaining 50% vest on the second anniversary, subject to continued service. The options have a 10-year term from the grant date, with acceleration upon involuntary termination without cause.

Following the transaction, the reporting person beneficially owned 731,000 derivative securities, held directly.

Rhea-AI Summary

Director sale of common stock reported. A director, Yaacov Nagar, reported a sale of 1,499,000 shares of 374Water Inc. (SCWO) executed on 10/08/2025 at a weighted-average price of $0.4641 per share. The filing shows the sale was made in multiple trades at prices between $0.4500 and $0.4891, and the reporting person retained 34,258,325 shares following the transactions. The Form 4 indicates the reporting person is a director and the form was signed on 10/10/2025.

Rhea-AI Summary

374Water Inc. director Yaacov Nagar reported a sale of 1,000 shares of common stock on 10/07/2025 at a price of $0.39 per share. After the sale, the reporting person beneficially owns 35,757,325 shares, reported as direct ownership. The Form 4 is a routine Section 16 filing that records this single non-derivative disposition and is signed by the reporting person on 10/09/2025. The filing contains no derivative transactions or additional explanatory notes.

Rhea-AI Summary

Stephen J. Jones, serving as Interim CEO and a director of 374Water Inc. (SCWO), was granted 4,500,000 stock options on 10/07/2025 as compensation for his appointment. The options have an exercise price of $0.37 per share and 25% of the grant vests on the vesting commencement date with additional 25% tranches vesting at 90, 180, and 270 days thereafter, subject to continued service. The options accelerate and vest immediately upon a change of control, hiring of a full‑time CEO, or termination other than for cause. Each vested option permits purchase of one share and options expire ten years from the applicable vesting date unless earlier terminated.